GLP-1, Ozempic & the Weight Loss Drug Revolution: What the Evidence Shows and What Comes Next
June 20, 2027
11:00 am – 11:30 am
Room 4
GLP-1 receptor agonists have transformed the weight loss landscape, but the clinical picture around long-term use, muscle preservation, cardiovascular benefit and what happens when you stop is more nuanced than the headlines suggest. Improve how you evaluate GLP-1 therapies as one component of a comprehensive, evidence-based weight management strategy. Source practical tips to:
- Decode what the clinical trial data actually demonstrates about GLP-1 efficacy, muscle loss risk, cardiovascular outcomes and long-term metabolic consequences
- Distinguish the candidates most likely to benefit from GLP-1 therapy from those for whom lifestyle intervention remains the stronger first-line approach
- Build a GLP-1 informed weight management protocol that maximises benefit, protects muscle mass and integrates pharmacological support with sustainable lifestyle change
Transform the weight loss outcomes the evidence supports, with a strategy that works beyond the prescription